Zoledronic Acid
Check Drug InteractionsCheck known drug interactions.
Check Drug InteractionsZoledronic Acid Prescribing Information
Zoledronic acid injection is a bisphosphonate indicated for:
• Treatment of Paget’s disease of bone in men and women
Infusion given intravenously over no less than 15 minutes:
• Treatment of Paget’s disease of bone: a single 5 mg infusion. Patients should receive 1500 mg elemental calcium and 800 international units vitamin D daily
5 mg in a 100 mL ready-to-infuse solution
• Pregnancy: Discontinue when pregnancy is recognized• Pediatric Use: Not indicated for use in pediatric patients• Geriatric Use: Special care to monitor renal function
• Hypocalcemia• Patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment• Hypersensitivity to any component of zoledronic acid injection
• Products Containing Same Active Ingredient: Patients receiving Zometa should not receive zoledronic acid• Hypocalcemiamay worsen during treatment. Patients must be adequately supplemented with calcium and vitamin D• Renal Impairment:A single dose should not exceed 5 mg and the duration of infusion should be no less than 15 minutes. Renal toxicity may be greater in patients with underlying renal impairment or with other risk factors, including advanced age or dehydration. Monitor creatinine clearance before each dose• Osteonecrosis of the Jaw (ONJ)has been reported. All patients should have a routine oral exam by the prescriber prior to treatment• Atypical Femur Fractureshave been reported. Patients with thigh or groin pain should be evaluated to rule out a femoral fracture• Severe Bone, Joint, and Muscle Painmay occur. Withhold future doses of zoledronic acid if severe symptoms occur
We receive information directly from the FDA and PrescriberPoint is updated as frequently as changes are made available